Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll New paradigms and tools in drug design for pain and addiction Hruby VJ; Porreca F; Yamamura HI; Tollin G; Agnes RS; Lee YS; Cai M; Alves I; Cowell S; Varga E; Davis P; Salamon Z; Roeske W; Vanderah T; Lai JAAPS J 2006[Jul]; 8 (3): E450-60New modalities providing safe and effective treatment of pain, especially prolonged pathological pain, have not appeared despite much effort. In this mini-review/overview we suggest that new paradigms of drug design are required to counter the underlying changes that occur in the nervous system that may elicit chronic pain states. We illustrate this approach with the example of designing, in a single ligand, molecules that have agonist activity at mu and delta opioid receptors and antagonist activities at cholecystokinin (CCK) receptors. Our findings thus far provide evidence in support of this new approach to drug design. We also report on a new biophysical method, plasmon waveguide resonance (PWR) spectroscopy, which can provide new insights into information transduction in G-protein coupled receptors (GPCRs) as illustrated by the delta opioid receptor.|Behavior, Addictive/*drug therapy[MESH]|Drug Design[MESH]|Opioid Peptides/*therapeutic use[MESH]|Pain Clinics[MESH]|Pain/*drug therapy[MESH]|Receptors, G-Protein-Coupled/antagonists & inhibitors[MESH]|Structure-Activity Relationship[MESH] |